We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$347M
AUM Growth
-$92.7M
Cap. Flow
-$125M
Cap. Flow %
-36.15%
Top 10 Hldgs %
71.88%
Holding
54
New
11
Increased
5
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.29M
2
A icon
Agilent Technologies
A
+$5.96M
3
ICLR icon
Icon
ICLR
+$5.89M
4
CNC icon
Centene
CNC
+$4.47M
5
RGEN icon
Repligen
RGEN
+$4.23M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$42.6M
2
NTRA icon
Natera
NTRA
+$12.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
4
DHR icon
Danaher
DHR
+$8.29M
5
MDT icon
Medtronic
MDT
+$8.06M

Sector Composition

Rank Sector Weight
1 Healthcare 98.84%
2 Consumer Staples 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
51
Wave Life Sciences
WVE
$1.13B
– –
-297,500
Closed -$2.18M
XENE icon
52
Xenon Pharmaceuticals
XENE
$6.28B
– –
-53,400
Closed -$2.14M
MTSR
53
DELISTED
Metsera Inc
MTSR
– –
-140,500
Closed -$7.35M
CARL
54
Carlsmed
CARL
$335M
– –
-321,912
Closed -$4.31M
1 2
3

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2025 Portfolio in Review

As of Q4 2025, Avidity Partners Management held 54 positions worth $347M, down 21% from $439M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Avidity Partners Management withdrew a net $125M in Q4 2025, closing 15 positions and reducing 19 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $11.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

Against the trend, Avidity Partners Management opened a new position in Alnylam Pharmaceuticals worth $8.35M.

  • Avidity Partners Management's largest Q4 2025 buy was Alnylam Pharmaceuticals: 21,000 shares worth $8.35M.
  • Avidity Partners Management added most to Repligen in Q4 2025, an estimated $4.23M increase.
  • Avidity Partners Management's biggest Q4 2025 reduction was Dianthus Therapeutics, cutting an estimated $42.6M.
  • Avidity Partners Management fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $11.6M.
  • Avidity Partners Management's ten largest holdings make up 72% of its $347M portfolio in Q4 2025.
  • Avidity Partners Management opened 11 new positions and closed 15 in Q4 2025.
  • Avidity Partners Management's portfolio value fell 21% quarter-over-quarter to $347M.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.